FY2023 Earnings Estimate for AC Immune SA Issued By SVB Leerink (NASDAQ:ACIU)

AC Immune SA (NASDAQ:ACIU – Get Rating) – Investment analysts at SVB Leerink increased their FY2023 earnings per share (EPS) estimates for shares of AC Immune in a research report issued to clients and investors on Monday, August 1st. SVB Leerink analyst M. Goodman now expects that the company will earn $0.63 per share for the year, up from their prior estimate of $0.62. SVB Leerink currently has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.98) per share. SVB Leerink also issued estimates for AC Immune’s FY2024 earnings at $0.16 EPS.

AC Immune (NASDAQ:ACIU – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01.

A number of other analysts have also recently commented on the company. StockNews.com assumed coverage on AC Immune in a research report on Wednesday, July 27th. They issued a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research report on Friday, June 17th.

AC Immune Stock Performance

Shares of ACIU opened at $3.42 on Wednesday. The company has a quick ratio of 13.28, a current ratio of 13.28 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $3.27 and its 200-day moving average price is $3.72. AC Immune has a 52 week low of $2.06 and a 52 week high of $12.61. The stock has a market cap of $285.33 million, a P/E ratio of -3.38 and a beta of 0.68.

Hedge Funds Weigh In On AC Immune

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACIU. Assenagon Asset Management S.A. bought a new position in AC Immune in the 4th quarter valued at approximately $730,000. Handelsbanken Fonder AB bought a new position in AC Immune in the 1st quarter valued at approximately $404,000. GSA Capital Partners LLP bought a new position in AC Immune in the 4th quarter valued at approximately $362,000. Metatron Capital SICAV plc bought a new position in AC Immune in the 4th quarter valued at approximately $218,000. Finally, Lombard Odier Asset Management Switzerland SA lifted its position in AC Immune by 9.2% in the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 348,196 shares of the company’s stock valued at $1,724,000 after acquiring an additional 29,451 shares in the last quarter. 26.49% of the stock is owned by institutional investors.

AC Immune Company Profile

(Get Rating)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading

• Get a free copy of the StockNews.com research report on AC Immune (ACIU)
• Two High-Yield Deep-Values You Shouldn’t Ignore 
• PayPal Continues To Struggle As Competition Increases
• Is Starbucks Shooting For The Moon? 
• AutoNation Stock is Firing on All Pistons
• Caterpillar Falls To Strong Support Near Bottom Of Range 

Want More Great Investing Ideas?